Management of Stage I Nonseminomatous Germ Cell Tumors

Kovac, Evan; Stephenson, Andrew J.

doi:10.1016/j.ucl.2015.04.004

Cited by 12 publications

(7 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Management of NSGCTs depends on the staging that includes a combination of active surveillance, retroperitoneal lymph node dissection (RPLND), and/or chemotherapy. For stage 1 NSGCTs with low risk of relapse post-orchiectomy, generally active surveillance is sufficient, while patients with more advance stage and/or higher risk of relapse may require a combination modality stated above [9]. Unfortunately, our patient had stage IV NSGCT.…”

Section: Figure 5: Testicular Germ Cell Tumor Pathologymentioning

confidence: 89%

Testicular Germ Cell Tumor Presenting to the Emergency Department

Rubero

Lee

Solomon

et al. 2021

Cureus

View full text Add to dashboard Cite

The authors report on a case of a patient who presented to the emergency department (ED) and was ultimately diagnosed with stage IV testicular non-seminomatous germ cell tumor. The patient was cachectic with a tumor on the neck, abdomen, and scrotum. Germ cell tumors (GCTs) exhibit characteristic symptoms at different points in development. Appropriate treatment can cure most GCTs. While cancer may not be thought of as an ED diagnosis, it can often be the place where patients first present, even when advanced. Recognizing it is important for prompt treatment.

show abstract

Section: Figure 5: Testicular Germ Cell Tumor Pathologymentioning

confidence: 89%

Testicular Germ Cell Tumor Presenting to the Emergency Department

Rubero

Lee

Solomon

et al. 2021

Cureus

View full text Add to dashboard Cite

show abstract

“…The overall relapse rate is 30% following orchiectomy. This means that 70% of patients are cured by orchiectomy alone, and by receiving adjuvant treatment they would be unnecessarily exposed to the potential adverse events 20 .…”

Section: Non-seminoma Stage Imentioning

confidence: 99%

“…following orchiectomy, there are 3 recommended options for the management of stage i non-seminoma, including active surveillance, adjuvant chemotherapy with 1-2 cycles of chemotherapy with PeB protocol, or primary nerve-sparing retroperitoneal lymph node dissection (p-RPlnD). each option has a cure rate of 99% 20 . At our Referral Center, as in other european high-volume centers, the preferred option for stage iA is active surveillance and for stage iB adjuvant chemotherapy with 1 cycle of PeB protocol.…”

Section: Non-seminoma Stage Imentioning

confidence: 99%

Treatment of Germ Cell Testicular Cancer

Kunac

Gnjidić

Golubić

et al. 2020

ACC

View full text Add to dashboard Cite

germ cell testicular cancer (gCTC) is a malignant neoplasm derived from the primordial germ cell. Although it accounts for approximately 1% of all malignancies in men, it is the most common cancer of younger male population, with the highest incidence between ages 15 and 35. Testicular cancer incidence rate has risen globally over the past several decades, with the average increase in the incidence of testicular cancer in Croatia of 7% per annum from the year 1983 to 2007. Two main groups are seminomas and non-seminomas, each accounting for 50% of cases, and they differ in treatment modalities and response to therapy. Despite increase in the incidence rate, a promising circumstance is that gCTC has become a model of curable cancer. Because of advances in diagnostic procedures, sophisticated radiation techniques and especially the introduction of cisplatin based chemotherapy protocols together with advanced postchemotherapy surgical techniques, curability is expected in about 95% of all patients diagnosed with testicular cancer and over 70% of patients with advanced disease. in this review, we will focus on treatment strategies of primary gCTC.

show abstract

“…Ako se limfadenektomijom dokažu histološki pozitivni limfni čvorovi, tada se indiciraju dva ciklusa adjuvantne kemoterapije prema protokolu BEP. [2][3][4]12 Stadij IB Kod bolesnika s neseminomskim rakom u testisu LVI je glavni rizični čimbenik za povrat bolesti (IIIB). Pri kombinaciji LVI-ja i patohistološkog nalaza embrionalnog raka testisa I. stadija povrat je bolesti neminovan (IIIB).…”

Section: Stadij Iaunclassified

“…U iznimnim situacijama praćenje je opcija kod bolesnika s tumorima T2 ili T3, ali se zbog višeg rizika od relapsa ne preporučuje. [2][3][4]12…”

Section: Stadij Iaunclassified